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Current vaccine strategies against influenza focus on
generating robust antibody responses. Because of the high
degree of antigenic drift among circulating influenza strains
over the course of a year, vaccine strains must be reformu-
lated specifically for each influenza season. The time delay
from isolating the pandemic strain to large-scale vaccine
production would be detrimental in a pandemic situation. A
vaccine approach based on cell-mediated immunity that
avoids some of these drawbacks is discussed here.
Specifically, cell-mediated responses typically focus on
peptides from internal influenza proteins, which are far less
susceptible to antigenic variation. We review the literature
on the role of CD4+ and CD8+ T cell–mediated immunity in
influenza infection and the available data on the role of
these responses in protection from highly pathogenic
influenza infection. We discuss the advantages of develop-
ing a vaccine based on cell-mediated immune responses
toward highly pathogenic influenza virus and potential
problems arising from immune pressure. 
V
accine approaches against respiratory virus infections
such as influenza have relied on inducing antibodies
that protect against viral infection by neutralizing virions
or blocking the virus’s entry into cells. These humoral
immune responses target external viral coat proteins that
are conserved for a given strain. Antibody-mediated pro-
tection is therefore effective against homologous viral
strains but inadequate against heterologous strains with
serologically distinct coat proteins. This distinction is of
consequence since many viruses rapidly mutate their coat
proteins; an effective humoral response–based vaccine
against a form of the virus may be ineffective against next
season’s variant. In contrast, T cells, which mediate cellu-
lar immune responses, can target internal proteins common
to heterologous viral strains. This property gives vaccines
that induce protective cellular immune responses the
potential to protect against heterologous viral strains. 
Antigen-specific ligation of T-cell receptors induces
effector mechanisms that either directly or indirectly pro-
mote lysis of infected cells. Functionally distinct T-cell
subsets are broadly identified according to their differen-
tial expression of CD4 and CD8 coreceptors. The CD4+ T
helper cells are primarily responsible for helping other
immune cells through direct cell-cell interactions or by
secreting cytokines after recognizing viral peptides bound
to major histocompatibility complex (MHC) class II mol-
ecules. The cytotoxic T lymphocytes (CTLs) typically
express CD8 and induce apoptosis of cells on which they
recognize foreign antigens presented by MHC class I mol-
ecules, providing a defense against intracellular pathogens
such as viruses. This association of phenotype and func-
tion is not absolute, since CD4+ cells may exhibit lytic
activity, while CD8+ cells secrete antiviral cytokines,
notably interferon-γ (IFN-γ) and tumor necrosis factor.
Greater understanding of how each subset contributes to
protective immunity and how T-cell memory is maintained
and recalled in a secondary infection would contribute to
development of effective vaccines that use these basic fea-
tures of the immune response.
Immune Models of Influenza
Influenza is a contagious, acute respiratory disease
caused by infection of the host respiratory tract mucosa by
an influenza virus (1). The influenza A viruses infect host
epithelial cells by attaching to a cellular receptor (sialic
acid) by the viral surface protein hemagglutinin (HA). The
virus is subsequently released because of the action of
another surface glycoprotein, the enzyme neuraminidase
(NA), several hours after infection.
Mouse models of influenza A virus pneumonia provide
a well-developed experimental system to analyze T
cell–mediated immunity. In particular, the T-cell immune
response to influenza infection has been well characterized
in C57BL/6 (B6,H2b) mice. While influenza infection of
mice does not precisely replicate the natural infection in
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of reagents and genetically modified mouse models has
enabled extensive analysis of the cellular immune
response. Emerging evidence indicates that findings from
mouse studies are pertinent to immunopathology in human
disease. In the BL/6 model, virus is cleared 10 days after
infection, with no indication of persistent antigen or viral
RNA (2). Recovery or prevention of influenza relies on
targeting both innate and adaptive responses to the respira-
tory tract mucosa.
CD8+ T-cell Response to Influenza
Much of the current knowledge on murine CD8+ T-cell
responses to influenza has come from analyzing the
response to challenge with the HKx31 (H3N2) and PR/8
(H1N1) influenza viruses. A role for CD8+ T cells in pro-
tective immunity has been discerned from studies citing
delayed influenza virus clearance in CD8+ T cell–deficient
mice (3,4). Furthermore, CD8+ T cells can promote recov-
ery from otherwise lethal secondary viral infections in
mice that lack mature B cells or antibodies (5,6), and
cloned influenza-specific CTLs can passively transfer pro-
tection (7). Despite a seemingly protective role for CD8+
T cells, vaccination with dominant influenza determinants
in either a vector or in a recombinant form is only mildly
protective (8–10). Moreover, in a T cell–receptor trans-
genic mouse model, devoid of antibodies, influenza-spe-
cific CTL can either contribute to survival or exacerbate
lethal influenza pneumonia (11). This study highlights the
need to understand the many facets of the immune
response to influenza. 
The influenza A virus–specific CD8+ T-cell response
has been characterized by using intracellular cytokine
staining and MHC class I tetramer labeling. These tech-
niques have enabled each phase of the response to be
tracked. After intranasal infection, priming, activation, and
expansion of naive influenza-specific CD8+ T cells occur
in the draining mediastinal lymph node 3–4 days after
infection (12,13). The antiviral capacity of these virus-spe-
cific CD8+ cells is strongly dependent on their ability to
migrate and localize to the lungs and infected airway
epithelium (14), where they appear 5–7 days after infec-
tion (15). Because viral replication is confined to cells in
the respiratory epithelium (16,17), CD8+ Tcells exert their
effector functions at this site, producing antiviral cytokines
and lysing target cells presenting viral determinants for
which they bear a specific T-cell receptor. Lysis of infect-
ed epithelial cells is mediated by exocytosis granules con-
taining perforin and granzymes (18,19). The release of
perforin and granzymes from influenza-specific CTLs is
tightly regulated, occurring shortly after activation at or
near the contact point between CTLs and the infected tar-
get cell (18).
Influenza-specific CD8+ T cells recognize multiple
viral epitopes on target cells and antigen-presenting cells.
The HKx31 and PR8 strains share 6 internal genes derived
from PR8 that are processed to generate peptides recog-
nized by influenza-specific CD8+ T cells. The primary
response to either strain is dominated by CD8+ T cells’
recognition of 2 determinants, the nucleoprotein (NP366-374,
H2Db) (20) and the acid polymerase (PA224-233, H2Db) (21).
A similarly low proportion of CD8+ T cells recognizes 4
other determinants: the basic polymerase subunit 1
(PB1703-711, H2Kb), nonstructural protein 2 (NS2114-121,
H2Kd), matrix protein 1 (M1128-135, H2Kb), and a protein
derived from an alternative open reading frame within the
PB1 gene (PB1-F262-70,H2Db) (22). The subsequent mem-
ory populations appears to be stable; DbNP366-374 and
DbPA224-233 CD8+ memory cells are still detectable >570
days after initial infection (K. Kedzierska and J. Stambas,
unpub. data).
Secondary influenza-specific CTL responses arise ≈2
days faster than the primary response, with a greatly
increased level of activity. Depletion of CD8+ T cells
reduces the capacity of primed mice to respond to influen-
za infection, which indicates a role for CD8+ T cells in the
protective secondary response. Prime and challenge exper-
iments can be conducted with HKx31 and PR/8 as all of
the recognized epitopes are derived from internal proteins.
Furthermore, cross-reactive neutralizing antibodies are
avoided because HKx31 and PR/8 express different sur-
face HA and NA or proteins. Despite a similar magnitude
to DbPA224-233 in the primary response, DbNP366-374-specif-
ic CD8+ T cells dominate the secondary response to
HKx31→PR/8 challenge, accounting for up to 80% of the
influenza-specific CD8+ T cells. This dominance is main-
tained in the memory population; the numbers of NP-spe-
cific CD8+ T cells exceed all other quantified
influenza-specific CD8+ T-cell populations (23). Despite
the NP dominance, CD8+ T cells specific for the other 5
determinants can still be isolated after secondary chal-
lenge, albeit at low frequency.
Conservation of these 6 internal genes and persistence
of the corresponding antigen-specific CD8+ T cells makes
these genes an attractive target for vaccine therapies.
However, although cell-mediated immunity can promote
viral clearance, it does not provide sterile resistance
because, unlike humoral immunity, it cannot prevent infec-
tion of the host cells. In humans, the level of influenza-spe-
cific CTLs correlates with the rate of viral clearance but
not with susceptibility to infection or subsequent illness
(24). Despite this limitation, vaccines that promote cell-
mediated immunity may be a favorable option to fight
potentially lethal, highly pathogenic influenza strains.
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In contrast to the body of literature that has character-
ized the role of CD8+ T cells specifically in models of
influenza infection, relatively little is known about the role
of CD4+ T cells as direct mediators of effector function.
That CD4+ T-cell help is central to adaptive immunity is
well established, but few antigen-specific systems have
been developed to dissect the role of CD4+ T cells in a
viral infection. While knowledge of CD8+ T-cell antigen-
specific responses has increased substantially in the past
several years as a result of tetramer technology, these
reagents have been more difficult to develop for the CD4+
subset. Further, identification of CD4+ T cell–specific epi-
topes has been less successful for a variety of pathogens.
For instance, in influenza, the CD8+ restricted epitopes
have all been largely identified for some time, particularly
in the BL/6 model system; in contrast, only very recently
have confirmed CD4 epitopes been found, and they are
much more poorly characterized (25).
Still, a substantial amount of work has been done with
various knockout, depletion, and cell-transfer models to
investigate the role of CD4+ T cells in primary, secondary,
and memory responses to influenza infection in the mouse
model (26,27). Controversy still exists in the field, and an
antigen-specific system would help address it, but certain
findings appear to be consistent across different experi-
mental systems (28).
In the primary response, CD4+ T cells are not required
for expansion or development of functional CD8+ CTL
(27,29), which may in part result from the ability of
influenza virus to directly activate dendritic cells, aiding in
the development of CD8+ responses that substitute for
functional CD4+ T cells (30). Similarly, in the case of a
murine  γ-herpesvirus, the lack of CD4+ T cells can be
compensated for by the addition of anti-CD40 stimulation
(31). In mice in which both the CD4+ T-cell and B-cell
compartments were defective, the primary CD8+ T-cell
response to influenza appeared to be stunted in terms of
recruitment and expansion (vs. mice in which B cells alone
were knocked out); the remaining CD8+ T cells had a
robust level of functionality as assayed by IFN-γ intracel-
lular cytokine production (27). The defect in the CD8+ T-
cell primary response was less obvious in mice with intact
B cells, though viral clearance was delayed. Still, not until
the secondary and memory responses are examined can the
dramatic effect of CD4+ T-cell deletion be observed.
In multiple systems, a defect of CD8+ T-cell secondary
and memory responses have been observed when the pri-
mary response lacks CD4+ T cells (26,32,33). In influen-
za, a dramatic drop was observed in the size and
magnitude of the recall response to secondary infection.
The rate of viral clearance was also slowed considerably,
beyond the degree seen in the primary response. Similarly,
in the Listeria monocytogenes model system, the primary
response was largely intact, while the long-term memory
response was defective (34). In mice that lacked CD4+ T
cells during the primary response, the memory pool of
CD8+ T cells was initially similar in size and functionali-
ty to that seen in wild-type mice but began to decline after
longer intervals, leading eventually to the recrudescence of
the infection. Secondary challenge also demonstrated a
reduced antigen-specific CD8+ T-cell compartment. 
In the influenza model, although the draining lymph
node and spleen CD8+ responses were defective in sec-
ondary infection of CD4+ T cell–deficient mice, the CD8+
T-cell responses in bronchoalveolar lavage were equiva-
lent to those seen in wild-type mice (29). This finding
implies that the high levels of activation and inflammation,
in large part mediated by innate immune effectors at the
site of infection, were capable of providing the right matu-
ration milieu to expand the response to wild-type levels;
this finding suggests CD4+ T cell–specific help is not
required at the site of the pathologic changes, at least when
the infection induces a high level of other immune stimu-
lation, though it is essential in the lymphoid organs in the
generation and maintenance of memory.
A role for CD4+ T cells as effectors has been found in
a number of other systems, including the mouse γ-her-
pesvirus model (35) and in HIV-infected humans (36,37).
In these studies, CD4+ T cells contribute to infection con-
trol by supplementing their helper role with cytotoxicity.
In the case of the γ-herpesvirus, the effector CD4+ popula-
tion was important only in immunoglobulin –/– µMT
mice, while the HIV studies were conducted in infected
(and presumably immune-irregular) patients. However,
effector CD4+ T cells have been found in multiple stages
of the disease and in long-term patients whose disease is
not progressing because viral replication is controlled.
Finally, a recent report demonstrated a similar cytotoxic
CD4+ T-cell effector population in protozoan-infected
cattle (38). 
Relatively few established mouse models are available
for studying the CD4+ response to influenza virus. On the
IAd BALB/c background, an HA epitope was discovered,
and a transgenic mouse was developed to analyze specific
responses (the HNT model) (39). This model has been
extremely useful for studying several aspects of CD4+
biology in influenza infection, particularly in regards to
aging and the development of primary responses leading to
acute memory (39). Several investigators have introduced
external epitopes in influenza to follow CD4+ T-cell
responses in defined systems. These include the hen egg
lysozyme p46–63 sequence (40) and the ovalbumin
323–339 (OT-II) epitope inserted into the NA stalk of
WSN influenza virus (41). We have inserted the OT-II epi-
tope into the HA of the PR8 H1N1 virus and the X31
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H3N2 virus. In contrast to the robust responses achieved
with CD8+ T-cell epitopes and transgenics, the CD4+ T-
cell responses seem relatively weak (unpub. data). Other
naturally occurring epitopes have similarly low frequen-
cies after infection (25). The antigen-specific CD4+
response may not develop the dramatic immunodominance
hierarchies that are well-known for CD8+ T cells and may
be directed at many epitopes, more than are seen in the
more-delimited CD8+ T-cell response. Much work needs
to be done before this conclusion is certain, and examples
of respiratory infections in mice produce robust and dom-
inant responses toward individual class II epitopes (42). 
Cell-mediated Protection against 
Highly Pathogenic Influenza
Highly pathogenic H5N1 influenza emerged in 1997,
followed by several waves of infection from 2002 until
now (43). The viruses have been remarkably virulent in
multiple animal models, including mice, but little work has
been done to characterize the protective immune respons-
es toward H5N1 viruses. A series of reports has shown
strong protection toward other highly pathogenic viruses
mediated by cellular responses, in the absence of neutral-
izing antibody. Antibody-deficient mice infected with a
mild, passaged strain of an H3N2 virus were more likely to
survive than naive controls when challenged with a highly
pathogenic H3N8 duck virus compared to naive controls
(44). A double-priming protocol provided increased pro-
tection from a lethal H7N7 challenge, which correlated
with an increased pool of cross-reactive antigen-specific
CD8+ T cells (45). In both these cases, the initial phase of
infection and viral growth seemed similar to that occurring
in immunologically naive mice, but a rapid decrease in
viral titers occurs after a few days of infection.
Since the emergence of the H5N1 viruses, concern has
arisen that the biological activity of these viruses, includ-
ing their diverse tissue tropism in a number of animal mod-
els, may influence the ability of immune responses to
control infection. Furthermore, some pathology associated
with these viruses has been attributed to extremely high
levels of inflammatory cytokines produced in response to
infection, which suggests a negative role for immune
responses. However, the few studies that have been per-
formed have shown promising results for the potential of
cell-mediated responses to contribute to the control of
infections. Aprime-challenge protocol using an H9N2 iso-
late with 98% homology to the internal genes of the
A/HongKong/156/97 H5N1 protected against the other-
wise lethal challenge (46) with a virus with a highly cleav-
able H5, a characteristic of all the pathogenic H5 viruses.
The priming protocol generated significant CTL activity
directed at the NP and PB2 proteins.
Our own work has indicated a similar ability of cell-
mediated immunity to protect against virulent H5N1 chal-
lenge. In a preliminary experiment, we primed mice with
the H1N1 PR8 strain and the H3N2 X31 strain followed by
a challenge with A/Vietnam/1203/2004, one of the most
lethal H5N1 viruses, which causes severe pathologic
changes, even in ducks. While 9 of 10 naive mice died, 9
of 10 primed mice survived past day 10 of infectious chal-
lenge and recovered substantial weight (Figure). The fact
that both groups lost weight indicated protection was
occurring by delayed cell-mediated responses, rather than
by the “immediate” cross-protective antibody response.
Cell-mediated Vaccine for 
Highly Pathogenic Influenza?
Despite the systems currently in place for manufactur-
ing and distributing an influenza vaccine, pandemic
influenza will require a substantially different approach.
The standard influenza vaccine given during the infectious
season is made from a reassortant seed strain containing
the HA and NA of the circulating virus with the internal
genes of a vaccine strain, usually PR8. The seed strain is
grown in eggs and is formaldehyde inactivated. This strat-
egy does not prime strong CD8 CTL responses, but it is
effective in providing antibody-mediated protection to
closely homologous strains (47). 
One drawback to this approach is the length of time
required to develop a seed strain, amplify it, and manufac-
ture it into distributable vaccine. In the case of a potential
influenza pandemic, the delivery of vaccine on this sched-
ule would not prevent the spread of the epidemic in many
countries. Furthermore, antigenic drift can occur between
the original selection of the seed strain and circulating
viruses before the vaccine is ready for distribution (48).
Figure. Apparent cell-mediated protection against highly patho-
genic H5N1 influenza virus. Mice (10 in each group) were immu-
nized by intraperitoneal injection of PR8, followed by
intraperitoneal injection 4 weeks later of X31. Four weeks after the
second immunization, immunized or naive mice were infected with
300 mouse lethal dose 50% of A/Vietnam/1203/2004.This problem was faced recently in a nonpandemic situa-
tion in 2003 and 2004 when the circulating Fujian strain of
H3N2 influenza had drifted from the vaccine strain (49).
While the Fujian strain was predicted to be circulating at
the time of vaccine delivery, a recombined seed strain
could not be isolated in time for vaccine production.
Although the ensuing influenza season was not as severe
as initially feared, the situation highlighted a problem with
the current vaccine strategy. Evidence of antigenic drift is
already evident in the most recent outbreaks of H5N1 (48).
Several groups have developed reverse genetics–based
methods that could speed the production of seed viruses as
well as proposals for growing viruses in cell culture rather
than in embyronated chicken eggs, which would allow for
a much faster scale up in response to an epidemic (50).
These technologies have not been approved yet for human
use, though trials are underway. 
Even if the development of recombinant seed strains by
reverse genetics becomes standard over the next few years,
questions remain about how effective the current
formaldehyde-inactivated seed strain strategies would be
against pandemic strains, particularly the currently circu-
lating H5N1 strains. Assuming that seed strains could be
produced rapidly, several weeks would be required to man-
ufacture a relevant number of doses of vaccine. To address
this concern, several governments have been stockpiling
vaccines based on H5N1 viruses that have been circulating
over the last few years. While these vaccines may provide
some protection, substantial evolution and antigenic drift
seem to be occurring, rendering the stockpiled strains less
and less useful (48). 
An approach based on conserved cellular epitopes
within the internal genes has the advantage of subverting
all of these issues. While cellular immunity is not steriliz-
ing, it prevents illness and death in animal models (3).
Common and immunodominant epitopes among circulat-
ing nonavian strains have been identified, and many of the
same models and algorithms can be used to make predic-
tions against the pathogenic strains (51). Mouse models
are now available that have human leukocyte antigen
(HLA) alleles, and they appear to recapitulate human epi-
tope use. As described earlier, protection against death
from highly pathogenic viruses has been shown in multiple
systems. Cross-protective cell-mediated immunity has
been found in birds for circulating chicken H5N1 and
H9N2, both of which have been suggested as potential
human pandemic strains (52). The notion of a “universal”
vaccine for highly pathogenic strains is attractive.
Antigenic drift due to immunologic pressure is also a
concern with a CD8- or CD4-based vaccine approach.
Reports have suggested that CD8+ epitopes under pressure
will mutate to escape protective immunity (11). The muta-
tion of an NP epitope that binds HLA-B35 present in
strains of virus from the 1930s through the present indi-
cates that even in nonpandemic years, immunologic pres-
sure from cross-protective CD8+ T cells is enough to drive
the evolution of the virus (53). In contrast, though, other
dominant epitopes do not appear to be under the same
pressure (54). 
Several human peptide epitopes that have been
described and characterized show evidence of remarkably
little mutation over many generations of viral evolution. In
the most recent outbreaks of H5N1 virus, some of these
peptides are conserved in viruses isolated from human
patients (Table). The conservation of so many peptides
from such distantly related viruses suggests that they may
be less susceptible to antigenic drift than the HA and NA
glycoproteins. Vaccines that promote strong memory CTL
activity toward these peptides and MHC, in combination
with the antibody-based approaches already underway,
could help prevent pandemic influenza. This approach
could potentiate immunologic pressure on the vaccine-tar-
geted epitopes, but an immunization strategy that targets a
large number of epitopes along with the natural restriction
on epitope structure due to viral function should mitigate
this effect. Some evidence shows that highly conserved
CTL epitopes are restricted from mutation by viral struc-
tural requirements. Given the large number of influenza
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reasonable assumptions about the identity of these epi-
topes in MHC-diverse populations and focus on how to
facilitate the development of strong immune responses
toward them. 
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